StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research report report published on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Marinus Pharmaceuticals Stock Down 0.2 %
Shares of Marinus Pharmaceuticals stock opened at $0.55 on Tuesday. The stock has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. The company has a 50-day simple moving average of $0.55 and a 200 day simple moving average of $0.76. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $9.41.
Institutional Investors Weigh In On Marinus Pharmaceuticals
A number of hedge funds have recently made changes to their positions in MRNS. World Investment Advisors LLC acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at about $104,000. Virtu Financial LLC acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $54,000. Jacobs Levy Equity Management Inc. increased its position in Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 117,255 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Marinus Pharmaceuticals by 1,968.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 126,752 shares in the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
See Also
- Five stocks we like better than Marinus Pharmaceuticals
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Breakout Stocks: What They Are and How to Identify Them
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
